Lantheus (NASDAQ:LNTH) Issues FY20 Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its FY20 earnings guidance on Tuesday morning. The company provided EPS guidance of $1.34 to $1.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.03. The company issued revenue guidance of $384 million to $390 million, compared to the consensus revenue estimate of $382.92 million.Lantheus also updated its FY 2020
Pre-Market guidance to 1.34-1.40 EPS.

NASDAQ:LNTH traded down $0.39 during midday trading on Wednesday, reaching $16.30. The stock had a trading volume of 699,539 shares, compared to its average volume of 405,727. Lantheus has a 1-year low of $15.53 and a 1-year high of $29.80. The firm’s fifty day simple moving average is $17.76 and its 200-day simple moving average is $20.46. The company has a debt-to-equity ratio of 1.84, a current ratio of 2.59 and a quick ratio of 2.08. The stock has a market capitalization of $650.96 million, a P/E ratio of 18.74 and a beta of 1.43.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Tuesday, February 25th. The medical equipment provider reported $0.34 EPS for the quarter, topping the consensus estimate of $0.30 by $0.04. The firm had revenue of $89.35 million for the quarter, compared to the consensus estimate of $90.62 million. Lantheus had a net margin of 10.02% and a return on equity of 46.58%. The business’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.29 EPS. On average, equities research analysts anticipate that Lantheus will post 1 earnings per share for the current fiscal year.

A number of equities analysts have recently commented on the company. ValuEngine upgraded Lantheus from a sell rating to a hold rating in a research note on Saturday, February 15th. BidaskClub upgraded Lantheus from a strong sell rating to a sell rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company. Lantheus currently has an average rating of Hold and an average price target of $29.00.

In other Lantheus news, Director Sam R. Leno sold 11,508 shares of the firm’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $20.30, for a total value of $233,612.40. Following the sale, the director now directly owns 38,072 shares in the company, valued at approximately $772,861.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Mary Anne Heino sold 9,898 shares of the firm’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.06, for a total transaction of $158,961.88. Following the completion of the sale, the chief executive officer now owns 556,014 shares in the company, valued at $8,929,584.84. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,017 shares of company stock valued at $926,373. Corporate insiders own 2.60% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Featured Story: How to Invest in an Index Fund

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with's FREE daily email newsletter.